Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib

Mi Young Jeon; Hye Won Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang Hyub Han; Song Ee Baek; Hye Soo Kim; Seung Up Kim; Mi Suk Park

doi:10.1111/liv.13731

Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib

Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Hyub Han, Song Ee Baek, Hye Soo Kim, Seung Up Kim, Mi Suk Park

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Background & Aims: The European Association for the Study of the Liver criteria and the modified Response Evaluation Criteria in Solid Tumors are used for assessing the treatment outcomes of hepatocellular carcinoma. We investigated the inter- and intra-observer reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients with advanced hepatocellular carcinoma treated with sorafenib. Methods: A total of 99 patients with treatment-naive advanced hepatocellular carcinoma receiving sorafenib were included. The κ-values for the inter- and intra-observer agreement of the treatment response were calculated. Results: Inter-observer agreement for baseline tumour number was excellent, as reflected by the high κ-value. The κ-statistics showed “excellent” concordance between the 2 sets of measurements by observer A regarding the overall responses using the European Association for the Study of the Liver criteria (κ =.948, agreement rate = 84.8%) and modified Response Evaluation Criteria in Solid Tumors (κ =.944, agreement rate = 83.8%; all P <.001). In addition, high κ-values indicated concordance between the first sets of measurements by observers A and B (κ =.991 by the European Association for the Study of the Liver criteria and.988 by modified Response Evaluation Criteria in Solid Tumors, all P <.001). When agreements in radiological overall responses between the 2 sets of measurements by observer B and between the second sets of measurements by observers A and B were calculated, similar results regarding high κ-values (>.8) were obtained. Conclusions: The reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in assessing treatment outcomes was high in patients with advanced hepatocellular carcinoma treated with sorafenib.

Original language	English
Pages (from-to)	1655-1663
Number of pages	9
Journal	Liver International
Volume	38
Issue number	9
DOIs	https://doi.org/10.1111/liv.13731
Publication status	Published - 2018 Sept

Bibliographical note

Funding Information:
Funding information This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (2016R1A1A1A05005138). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. The authors are grateful to Dong-Su Jang (Medical Illustrator, Medical Research Support Section, Yonsei University College of Medicine, Seoul, Republic of Korea) for his help with the figures.

Funding Information:
This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (2016R1A1A1A05005138). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.

Publisher Copyright:
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

All Science Journal Classification (ASJC) codes

Hepatology

Access to Document

10.1111/liv.13731

Cite this

Jeon, M. Y., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Han, K. H., Baek, S. E., Kim, H. S., Kim, S. U., & Park, M. S. (2018). Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. Liver International, 38(9), 1655-1663. https://doi.org/10.1111/liv.13731

@article{845ae41ac75f4128acc334a25485eecb,

title = "Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib",

abstract = "Background & Aims: The European Association for the Study of the Liver criteria and the modified Response Evaluation Criteria in Solid Tumors are used for assessing the treatment outcomes of hepatocellular carcinoma. We investigated the inter- and intra-observer reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients with advanced hepatocellular carcinoma treated with sorafenib. Methods: A total of 99 patients with treatment-naive advanced hepatocellular carcinoma receiving sorafenib were included. The κ-values for the inter- and intra-observer agreement of the treatment response were calculated. Results: Inter-observer agreement for baseline tumour number was excellent, as reflected by the high κ-value. The κ-statistics showed “excellent” concordance between the 2 sets of measurements by observer A regarding the overall responses using the European Association for the Study of the Liver criteria (κ =.948, agreement rate = 84.8%) and modified Response Evaluation Criteria in Solid Tumors (κ =.944, agreement rate = 83.8%; all P <.001). In addition, high κ-values indicated concordance between the first sets of measurements by observers A and B (κ =.991 by the European Association for the Study of the Liver criteria and.988 by modified Response Evaluation Criteria in Solid Tumors, all P <.001). When agreements in radiological overall responses between the 2 sets of measurements by observer B and between the second sets of measurements by observers A and B were calculated, similar results regarding high κ-values (>.8) were obtained. Conclusions: The reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in assessing treatment outcomes was high in patients with advanced hepatocellular carcinoma treated with sorafenib.",

author = "Jeon, {Mi Young} and Lee, {Hye Won} and Kim, {Beom Kyung} and Park, {Jun Yong} and Kim, {Do Young} and Ahn, {Sang Hoon} and Han, {Kwang Hyub} and Baek, {Song Ee} and Kim, {Hye Soo} and Kim, {Seung Up} and Park, {Mi Suk}",

note = "Funding Information: Funding information This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (2016R1A1A1A05005138). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. The authors are grateful to Dong-Su Jang (Medical Illustrator, Medical Research Support Section, Yonsei University College of Medicine, Seoul, Republic of Korea) for his help with the figures. Funding Information: This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (2016R1A1A1A05005138). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. Publisher Copyright: {\textcopyright} 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",

year = "2018",

month = sep,

doi = "10.1111/liv.13731",

language = "English",

volume = "38",

pages = "1655--1663",

journal = "Liver International",

issn = "1478-3223",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib

AU - Jeon, Mi Young

AU - Lee, Hye Won

AU - Kim, Beom Kyung

AU - Park, Jun Yong

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Han, Kwang Hyub

AU - Baek, Song Ee

AU - Kim, Hye Soo

AU - Kim, Seung Up

AU - Park, Mi Suk

N1 - Funding Information: Funding information This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (2016R1A1A1A05005138). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. The authors are grateful to Dong-Su Jang (Medical Illustrator, Medical Research Support Section, Yonsei University College of Medicine, Seoul, Republic of Korea) for his help with the figures. Funding Information: This study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (2016R1A1A1A05005138). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. Publisher Copyright: © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

PY - 2018/9

Y1 - 2018/9

N2 - Background & Aims: The European Association for the Study of the Liver criteria and the modified Response Evaluation Criteria in Solid Tumors are used for assessing the treatment outcomes of hepatocellular carcinoma. We investigated the inter- and intra-observer reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients with advanced hepatocellular carcinoma treated with sorafenib. Methods: A total of 99 patients with treatment-naive advanced hepatocellular carcinoma receiving sorafenib were included. The κ-values for the inter- and intra-observer agreement of the treatment response were calculated. Results: Inter-observer agreement for baseline tumour number was excellent, as reflected by the high κ-value. The κ-statistics showed “excellent” concordance between the 2 sets of measurements by observer A regarding the overall responses using the European Association for the Study of the Liver criteria (κ =.948, agreement rate = 84.8%) and modified Response Evaluation Criteria in Solid Tumors (κ =.944, agreement rate = 83.8%; all P <.001). In addition, high κ-values indicated concordance between the first sets of measurements by observers A and B (κ =.991 by the European Association for the Study of the Liver criteria and.988 by modified Response Evaluation Criteria in Solid Tumors, all P <.001). When agreements in radiological overall responses between the 2 sets of measurements by observer B and between the second sets of measurements by observers A and B were calculated, similar results regarding high κ-values (>.8) were obtained. Conclusions: The reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in assessing treatment outcomes was high in patients with advanced hepatocellular carcinoma treated with sorafenib.

AB - Background & Aims: The European Association for the Study of the Liver criteria and the modified Response Evaluation Criteria in Solid Tumors are used for assessing the treatment outcomes of hepatocellular carcinoma. We investigated the inter- and intra-observer reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients with advanced hepatocellular carcinoma treated with sorafenib. Methods: A total of 99 patients with treatment-naive advanced hepatocellular carcinoma receiving sorafenib were included. The κ-values for the inter- and intra-observer agreement of the treatment response were calculated. Results: Inter-observer agreement for baseline tumour number was excellent, as reflected by the high κ-value. The κ-statistics showed “excellent” concordance between the 2 sets of measurements by observer A regarding the overall responses using the European Association for the Study of the Liver criteria (κ =.948, agreement rate = 84.8%) and modified Response Evaluation Criteria in Solid Tumors (κ =.944, agreement rate = 83.8%; all P <.001). In addition, high κ-values indicated concordance between the first sets of measurements by observers A and B (κ =.991 by the European Association for the Study of the Liver criteria and.988 by modified Response Evaluation Criteria in Solid Tumors, all P <.001). When agreements in radiological overall responses between the 2 sets of measurements by observer B and between the second sets of measurements by observers A and B were calculated, similar results regarding high κ-values (>.8) were obtained. Conclusions: The reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in assessing treatment outcomes was high in patients with advanced hepatocellular carcinoma treated with sorafenib.

UR - http://www.scopus.com/inward/record.url?scp=85044788627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044788627&partnerID=8YFLogxK

U2 - 10.1111/liv.13731

DO - 10.1111/liv.13731

M3 - Article

C2 - 29495116

AN - SCOPUS:85044788627

SN - 1478-3223

VL - 38

SP - 1655

EP - 1663

JO - Liver International

JF - Liver International

IS - 9

ER -

Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this